Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Theranostic Advances in Vascular Malformations.

Dekeuleneer V, Seront E, Van Damme A, Boon LM, Vikkula M.

J Invest Dermatol. 2020 Apr;140(4):756-763. doi: 10.1016/j.jid.2019.10.001. Review.

PMID:
32200879
2.

c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis.

Van den Bossche V, Jadot G, Grisay G, Pierrard J, Honoré N, Petit B, Augusto D, Sauvage S, Laes JF, Seront E.

Target Oncol. 2020 Feb;15(1):139-146. doi: 10.1007/s11523-020-00704-2.

PMID:
32020516
3.

Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review.

Pierrard J, Seront E.

Curr Oncol. 2019 Dec;26(6):395-403. doi: 10.3747/co.26.5177. Epub 2019 Dec 1. Review.

4.

Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab.

Pierrard J, Petit B, Lejeune S, Seront E.

BMJ Case Rep. 2019 Aug 21;12(8). pii: e230848. doi: 10.1136/bcr-2019-230848.

PMID:
31439558
5.

Cascade of immunologic adverse events related to pembrolizumab treatment.

Dhenin A, Samartzi V, Lejeune S, Seront E.

BMJ Case Rep. 2019 Jun 4;12(6). pii: e229149. doi: 10.1136/bcr-2018-229149.

PMID:
31167767
6.

May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?

Bossi P, Seront E, Machiels JP.

Oral Oncol. 2019 Jul;94:121-122. doi: 10.1016/j.oraloncology.2019.05.011. Epub 2019 May 21. No abstract available.

PMID:
31126715
7.

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.

Seront E, Schmitz S, Papier M, van Maanen A, Henry S, Lonchay C, Rottey S, van Caloen G, Machiels JP.

Front Oncol. 2019 Mar 19;9:155. doi: 10.3389/fonc.2019.00155. eCollection 2019.

8.

Rapamycin and treatment of venous malformations.

Seront E, Van Damme A, Boon LM, Vikkula M.

Curr Opin Hematol. 2019 May;26(3):185-192. doi: 10.1097/MOH.0000000000000498.

PMID:
30855337
9.

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.

Seront E, Catala G, Dermine A, Lejeune S, Rysselinck S.

Future Sci OA. 2018 Oct 4;4(10):FSO341. doi: 10.4155/fsoa-2018-0033. eCollection 2018 Dec. Review.

10.

Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.

Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, Hoyoux C, Chopinet C, Clapuyt P, Hammer F, Vikkula M, Boon LM.

Orphanet J Rare Dis. 2018 Oct 29;13(1):191. doi: 10.1186/s13023-018-0934-z.

11.

Venous Malformations of the Head and Neck.

Seront E, Vikkula M, Boon LM.

Otolaryngol Clin North Am. 2018 Feb;51(1):173-184. doi: 10.1016/j.otc.2017.09.003. Review.

PMID:
29217061
12.

Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancer.

van Marcke C, Seront E, Docquier C, Filleul B.

Clin Exp Dermatol. 2017 Apr;42(3):328-330. doi: 10.1111/ced.13071. Epub 2017 Feb 27.

PMID:
28239882
13.

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.

Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D, Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S.

Oncologist. 2016 Dec;21(12):1416-e17. Epub 2016 Nov 30.

14.

[Rapamycin opens the era of targeted molecular therapy of venous malformations].

Seront E, Limaye N, Boon LM, Vikkula M.

Med Sci (Paris). 2016 Jun-Jul;32(6-7):574-8. doi: 10.1051/medsci/20163206016. Epub 2016 Jul 12. French. No abstract available.

15.

Atypical case of ecthyma gangrenosum mimicking a breast cancer recurrence.

Seront E, Kidd F, Metz T, Van Ruyssevelt P.

BMJ Case Rep. 2016 Mar 30;2016. pii: bcr2016214349. doi: 10.1136/bcr-2016-214349.

16.

Unusual presentation of bladder cancer resurgence and efficacy of radiotherapy.

Galot R, Christian N, Bitar M, Seront E.

BMJ Case Rep. 2016 Jan 27;2016. pii: bcr2015213538. doi: 10.1136/bcr-2015-213538.

17.

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.

Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP.

BJU Int. 2016 Sep;118(3):408-15. doi: 10.1111/bju.13415. Epub 2016 Feb 11.

18.

Rapid and fatal acute heart failure induced by pazopanib.

van Marcke C, Ledoux B, Petit B, Seront E.

BMJ Case Rep. 2015 Sep 2;2015. pii: bcr2015211522. doi: 10.1136/bcr-2015-211522.

19.

Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.

Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, Mendola A, Natynki M, Seront E, Dupont S, Hammer J, Legrand C, Brugnara C, Eklund L, Vikkula M, Bischoff J, Boon LM.

J Clin Invest. 2015 Sep;125(9):3491-504. doi: 10.1172/JCI76004. Epub 2015 Aug 10.

20.

Molecular biology and targeted therapies for urothelial carcinoma.

Seront E, Machiels JP.

Cancer Treat Rev. 2015 Apr;41(4):341-53. doi: 10.1016/j.ctrv.2015.03.004. Epub 2015 Mar 24. Review.

PMID:
25828962
21.

Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.

Draoui N, Schicke O, Seront E, Bouzin C, Sonveaux P, Riant O, Feron O.

Mol Cancer Ther. 2014 Jun;13(6):1410-8. doi: 10.1158/1535-7163.MCT-13-0653. Epub 2014 Mar 26.

22.

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours.

Seront E, Boidot R, Bouzin C, Karroum O, Jordan BF, Gallez B, Machiels JP, Feron O.

Br J Cancer. 2013 Nov 12;109(10):2597-606. doi: 10.1038/bjc.2013.644. Epub 2013 Oct 24.

23.

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.

Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.

Br J Cancer. 2013 Sep 17;109(6):1586-92. doi: 10.1038/bjc.2013.505. Epub 2013 Aug 29.

24.

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP.

Ann Oncol. 2012 Oct;23(10):2663-70. Epub 2012 Apr 3.

25.

New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.

Seront E, Mazzeo F, Mano M, Sterckx M, Humblet Y, Machiels JP, Baurain JF.

Acta Clin Belg. 2011 Nov-Dec;66(6):426-8.

PMID:
22338305
26.

Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases?

Seront E, Van den Eynde M.

Clin Colorectal Cancer. 2012 Sep;11(3):177-84. doi: 10.1016/j.clcc.2011.12.004. Epub 2012 Feb 10. Review.

PMID:
22306027
27.

Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.

Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y.

Cancer Treat Rev. 2010 Feb;36 Suppl 1:S11-4. doi: 10.1016/S0305-7372(10)70002-5.

PMID:
20189054
28.

Targeted therapies in the treatment of advanced renal cell carcinoma.

Seront E, Machiels JP.

Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):146-56. Review.

PMID:
19519537
29.

About two intra-aortic masses.

Seront E, de Saint-Hubert G, Gilbeau JP, Van Ruyssevelt P, Derue G.

Eur J Intern Med. 2008 Oct;19(6):e15-7. doi: 10.1016/j.ejim.2007.12.001. Epub 2008 Feb 11. No abstract available.

PMID:
18848158

Supplemental Content

Loading ...
Support Center